Cargando…

Design and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor Activity

Immune-checkpoint blockades, suchas PD-1 monoclonal antibodies, have shown new promising avenues to treat cancers. Failure responsesof many cancer patients to these agents have led to a massive need for alternative strategies to optimize tumor immunotherapy. Currently, new therapeutic developments i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abbas, Abdul Baset, Lin, Bingjing, Liu, Chen, Morshed, Arwa, Hu, Jialiang, Xu, Hanmei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386944/ https://www.ncbi.nlm.nih.gov/pubmed/30699956 http://dx.doi.org/10.3390/ijms20030572

Ejemplares similares

Shedding New Light on The Role of ανβ3 and α5β1 Integrins in Rheumatoid Arthritis
por: Morshed, Arwa, et al.
Publicado: (2019)

An antitumor peptide RS17‐targeted CD47, design, synthesis, and antitumor activity
por: Wang, Xinmin, et al.
Publicado: (2021)

Anti-Tumor Activity and Pharmacokinetics of AP25-Fc Fusion Protein
por: Pei, Dening, et al.
Publicado: (2019)

Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis
por: Hu, Jialiang, et al.
Publicado: (2019)

Retraction Note: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis
por: Hu, Jialiang, et al.
Publicado: (2020)

Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide
por: Zhang, Erhao, et al.
Publicado: (2018)

Design and Synthesis of Novel Pyrazole-Substituted Different Nitrogenous Heterocyclic Ring Systems as Potential Anti-Inflammatory Agents
por: Nossier, Eman S., et al.
Publicado: (2017)

Significantly increased anti‐tumor activity of carcinoembryonic antigen‐specific chimeric antigen receptor T cells in combination with recombinant human IL‐12
por: Chi, Xiaowei, et al.
Publicado: (2019)

Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors
por: Caldwell, Charles, et al.
Publicado: (2017)

Tumor-related interleukins: old validated targets for new anti-cancer drug development
por: Setrerrahmane, Sarra, et al.
Publicado: (2017)

Synthesis and Preclinical Evaluation of the Fibrin-Binding Cyclic Peptide (18)F-iCREKA: Comparison with Its Contrasted Linear Peptide
por: Zhang, Yin, et al.
Publicado: (2019)

Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists
por: Butera, Roberto, et al.
Publicado: (2021)

A human receptor occupancy assay to measure anti‐PD‐1 binding in patients with prior anti‐PD‐1
por: Junker, Fabian, et al.
Publicado: (2021)

Tumor-Derived EV-Encapsulated miR-181b-5p Induces Angiogenesis to Foster Tumorigenesis and Metastasis of ESCC
por: Wang, Ying, et al.
Publicado: (2020)

Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma(☆)
por: Chung, Eun Ji, et al.
Publicado: (2013)

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
por: Zhang, Hao, et al.
Publicado: (2023)

Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer
por: Kaufman, Bar, et al.
Publicado: (2023)

Optimized functional and structural design of dual-target LMRAP, a bifunctional fusion protein with a 25-amino-acid antitumor peptide and GnRH Fc fragment
por: Li, Meng, et al.
Publicado: (2020)

Evaluation of the antitumor activity of moronecidin (Piscidin)-like peptide in combination with anti-PD-1 antibody against melanoma tumor
por: Mohammadi, Mohsen, et al.
Publicado: (2023)

Design and Synthesis of Binding Growth Factors
por: Tada, Seiichi, et al.
Publicado: (2012)

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019)

Improved scFv Anti-LOX-1 Binding Activity by Fusion with LOX-1-Binding Peptides
por: Hu, Wei, et al.
Publicado: (2017)

Anti-tumor effects of anti-PD-L1 therapy in an orthotopic bladder tumor model
por: Lyon, Amanda, et al.
Publicado: (2014)

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
por: Chen, Jiming, et al.
Publicado: (2022)

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
por: Mabbitt, Joseph, et al.
Publicado: (2023)

Design of Protein Segments and Peptides for Binding to Protein Targets
por: Gupta, Suchetana, et al.
Publicado: (2022)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy
por: Yoo, Jae Do, et al.
Publicado: (2020)

Rational design of a potent macrocyclic peptide inhibitor targeting the PD-1/PD-L1 protein–protein interaction
por: Miao, Qi, et al.
Publicado: (2021)

EGFR-Binding Peptides: From Computational Design towards Tumor-Targeting of Adeno-Associated Virus Capsids
por: Feiner, Rebecca C., et al.
Publicado: (2020)

Surgical excision and oncoplastic breast surgery in 32 patients with benign phyllodes tumors
por: Ren, Jie, et al.
Publicado: (2018)

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
por: Liu, Hao, et al.
Publicado: (2019)

Plant Viral Nanoparticle Conjugated with Anti-PD-1 Peptide for Ovarian Cancer Immunotherapy
por: Gautam, Aayushma, et al.
Publicado: (2021)

Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
por: Wang, Yue, et al.
Publicado: (2023)

Peptide crosslinked micelles: a new strategy for the design and synthesis of peptide vaccines
por: Hao, Jihua, et al.
Publicado: (2006)

An Efficient Approach for the Design and Synthesis of Antimicrobial Peptide-Peptide Nucleic Acid Conjugates
por: Patil, Nitin A., et al.
Publicado: (2022)

The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions
por: Zhang, Tong, et al.
Publicado: (2018)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
por: Zhang, Lin, et al.
Publicado: (2020)

Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer
por: Lu, Lu, et al.
Publicado: (2022)

A d-peptide-based oral nanotherapeutic modulates the PD-1/PD-L1 interaction for tumor immunotherapy
por: Liu, Dan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_083dl6usuoipgdjbco930ui62u